 |
|
|
|
 |
|
|
Olmesartan
|
|
Olmesartan
|
| Systematic (IUPAC) name |
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[ [4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate |
| Identifiers |
| CAS number |
144689-63-4 |
| ATC code |
C09CA08 |
| PubChem |
130881 |
| DrugBank |
APRD00223 |
| Chemical data |
| Formula |
C29H30N6O6 |
| Mol. mass |
558.585 g/mol |
| Pharmacokinetic data |
| Bioavailability |
Rapid and complete absorption |
| Metabolism |
Hepatic (cannot be removed by hemodialysis) |
| Half life |
13 hours |
| Excretion |
Primarily fecal, 35%-50% in urine |
| Therapeutic considerations |
| Pregnancy cat. |
C (D if used in second or third trimester)
|
| Legal status |
℞ Prescription only
|
| Routes |
Oral |
Olmesartan (Benicar®,Olmetec®) belongs to the class of medicines called angiotensin II receptor antagonists to treat high blood pressure. It is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. and Forest Laboratories. Olmesartan works by blocking the binding of angiotension II to the AT1 receptors in vascular muscle; it is therefore independent of angiotension II synthesis pathways, unlike ACE inhibitors. By blocking binding rather than synthesis of angiotension II, olmesartan inhibits the negative regulatory feedback on renin secretion. As a result of this blockage, olmesartan restricts vasoconstriction and the secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing peripheral resistance.
Administration
Olmesartan is available in 5, 20, and 40 mg tablets. A normal dose for an adult (including the elderly and mild renal or hepatic impairment) is 20 mg/day in one dosage. This may be increased after two weeks to 40 mg/day if further blood pressure reduction is needed.
Side effects
Side effects include:
References
Hodgson, Barbara B., and Kizior, Robert J. Saunders Nursing Drug Handbook 2006. St. Louis, MO: Elsevier, Saunders, 2006.
|
| |
|
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Olmesartan". A list of authors is available in Wikipedia.
|
|
|
|
|
|
Top